Cost-effectiveness of boceprevir in the combination therapy of hepatitis C virus infection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic infection caused by hepatitis C virus (HCV) is one of the main causes of liver diseases. According to the World Health Organization, there are now 130-170 million HCV-infected patients worldwide, who are at high risk for liver damages, such as liver cirrhosis or cancer. Based on the clinical findings of the efficacy and safety of the novel group of antiherpetic agents (protease inhibitors), boceprevir, a representative of this group, was officially recommended in 2011 for the treatment of HCV genotype 1 infection, in combination with a pegylated interferon alfa and ribavirin. This triple therapy can substantially reduce the negative sequels of HCV infection; however, it is associated with increased drug therapy costs, so it is important to objectively assess the results of therapy involving boceprevir in terms of the long-term prognosis of the disease. The objective of this paper was to assess the cost-effectiveness of this therapy, by taking into account its clinical efficacy and safety, as well as its impact on the development of complications of HCV infections.

Full Text

Restricted Access

About the authors

E. A Ushkalova

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: eushk@yandex.ru

Yu. Sh Gushchina

Peoples' Friendship University of Russia

Email: gushchina@mail.ru

References

  1. Deuffic-Burban S., Poynard T., Sulkowski M.S., Wong J.B. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus in the United States. J. Viral. Hepat. 2007; 14: 107-115.
  2. Singal A.G., Volk M.L., Jensen D., Di Bisceglie A.M., Schoenfeld P.S. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin. Gastroenterol. Hepatol. 2010; 8: 280-288.
  3. World Health Organization (WHO). Hepatitis: facts and figures. 2010. http://www.euro.who.int/en/what-we-do/health-topics/ communicable-diseases/hepatitis/facts-and-figures/hepatitis-c (accessed September 9, 2011)
  4. Рекомендации по диагностике и лечению взрослых больных гепатитом С. 2013 г. http://hcv.ru/deseas/treat/hcv_rekomend_2013. html
  5. Дерябин П.Г. Распространение гепатита С в России становится социальной проблемой. СанЭпидемКонтроль 2009; 4 http://www.profiz.ru/sec/4_2009/gepatit_C
  6. Te H.S., Jensen D.M. Epidemiology of hepatitis B and C viruses: a global overview. Clin. Liver Dis. 2010; 13(1): 1-21. doi: 10.1016/j. cld.2009.11.009. vii.
  7. Centers for Disease Control and Prevention. Hepatitis C FAQs for Health Professionals. Last updated: December 17, 2010. Available at: http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm#. Accessed February 8, 2011.
  8. El Khoury A.C., Klimack W.K., Wallace C., Razavi H. Economic burden of hepatitic C associated diseases in the United States. J. Viral. Hepat. 2012; 13(3): 153-160. doi: 10.1111/j.1365-2893.2011.01563.x.
  9. Mathis A.S. Economic burden and current managed care challenges associated with hepatitis C. Am. J. Manag. Care 2012; 18(Suppl 14): 350-359.
  10. United States Bureau of Labor Statistics. Inflation Calculator CPI. www.bls.gov/data/inflation_calculator.htm
  11. Davis G.L., Albright J.E., Cook S.F., Rosenberg D.M. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003; 13(4): 331-338.
  12. Gellad Z.F., Reed S.D., Muir A.J. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir. Ther. 2012; 17(6, Pt B): 1189-1199.
  13. Deuffic-Burban S., Poynard T., Sulkowski M.S., Wong J.B. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus in the United States. J. Viral. Hepat. 2007; 14: 107-115.
  14. Shatin D., Schech S.D., Patel K. et al. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am. J. Manag. Care. 2004; 10: 250-256.
  15. Volk M.L., Tocco R., Saini S., Lok A.S.F. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 1750-1755.
  16. Razavi H., El Khoury A., Elbasha E., Estes C., Pasini K., Poynard T. et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatol. 2012. http://www.natap. org/2013/HCV/26218_fta.pdf
  17. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S. et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011;.13(13):1195-1206. doi: 10.1056/NEJMoa1010494.
  18. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958.
  19. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S. et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 13: 1207-1217. doi: 10.1056.
  20. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H. et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 13: 2407-2416.
  21. Ferrante S.A., Chhatwal J., Brass C.A., El Khoury A.C., Poordad F., Bronowicki J.-P. et al. Boceprevir for previously untreated patients with chronic hepatitis C genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect. Dis. 2013; 13: 190. doi: 10.1186/1471-2334-13-190.
  22. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Hepatol. 2011; 54(4): 1433-1444.
  23. Wilby K.J., Partovi N., Ford J.A., Greanya E., Yoshida E.M. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can. J. Gastroenterol. 2012; 26(4): 205-210.
  24. Soriano V., Labarga P., Fernández-Montero J.V., Benito J.M., Poveda E., Rallon N. et al. The changing face of hepatitis C in the new era of direct-acting antivirals. Antiviral Res. 2013; 97(1): 36-40. doi: 10.1016/j.antiviral.2012.10.011. Epub 2012 Nov 9.
  25. Chapman R.H., Berger M., Weinstein M.C., Weeks J.C., Goldie S., Neumann P.J. When does quality-adjusting life-years matter in cost-effectiveness analysis? Health. Econ. 2004; 13: 429-436.
  26. O’Brien В. Principles of economic evaluation for healti care programs. J. Rheumatol. 1995: 22(7): 1399-1402.
  27. Kuppermann М., Luce B.R., McGovern В. et al. An analysis of the cost effectiveness of the implantable defibrillator. Circulation 1990; 81: 91-100.
  28. Wong J.B. Hepatitis C. Cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24: 661-672.
  29. Ferrante S.A., Chhatwal J., Brass C.A., El Khoury A.C., Poordad F., J.-P. Bronowicki J.-P. et al. Boceprevir for previously untreated patients with chronic hepatitis C genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis. 2013; 13(1): 190.
  30. Chhatwal J., Ferrante S.A., Dasbach E.J., Khoury A. E., Bacon B., Burroughs M. et al. Cost- effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with Peginterferon/Ribavirin. 62th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco: AASLD., 2011.
  31. Chan K., Lai M.N., Groessl E.J., Hanchate A.D., Wong J.B., Clark J.A. et al. Cost-effectiveness analysis of direct-acting antiviral therapy for treatment-naïve patients with chronic hepatitis C genotype 1 infection in the veterans health administration. Clin. Gastroenterol. Hepatol. 2013 May 22. pii: S1542-3565(13)00705-2. doi: 10.1016/j.cgh.2013.05.014.
  32. Cammà C., Petta S., Enea M. et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-860.
  33. Gao X., Stephens J.M., Carter J.A., Haider S., Rustgi V.K. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev. Pharmacoecon. Outcomes Res. 2012; 12: 335-343.
  34. Liu S., Schwarzinger M., Carrat F., Goldhaber-Fiebert J.D. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS ONE 2011; 6(12): e26783. doi:10.1371/ journal.pone.0026783.
  35. Elbasha E.H., Chhatwal J., Ferrante S.A., El Khoury A.C., Laires P.A. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl. Health Econ. Health Policy. 2013; 11(1): 65-78. doi: 10.1007/ s40258-012-0007-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies